Riluzole is being assessed, with promising results, in advanced melanoma patients included in phase II clinical trials.267 Reminiscent of uveal melanoma driven by mutant Gq/11,51 which in preclinical studies is sensitive to FR900359,268 the mGluR1/Gq signaling pathway emerges as a potential target in melanoma. The gene discussed is GRM1; the disease is melanoma.